ADAR1 Capital Management, LLC and Daniel Schneeberger, a ten-percent owner and manager of ADAR1, collectively acquired shares of Rallybio Corp (NASDAQ:RLYB) common stock valued at approximately $226,563, according to a recent SEC filing. The purchases occurred over two days, May 18 and May 19, 2026.
The transactions involved the acquisition of 16,209 shares. On May 18, 6,009 shares were purchased at a weighted average price of $13.9759 per share. Further acquisitions on May 19 included 10,000 shares at $13.9822 average, and an additional 200 shares at $13.80. Prices ranged from $13.80 to $13.9822 across all purchases.
Rallybio trades at $14.58, near its 52-week high of $15.31, following a 459% return over the past year. According to Bond.az analysis, the stock appears overvalued relative to its Fair Value. The platform offers 13 additional ProTips and comprehensive financial metrics for investors.
The acquired securities are held indirectly through private investment funds managed by ADAR1 Capital Management. Daniel Schneeberger may be deemed to indirectly beneficially own these securities. Both reporting persons disclaim beneficial ownership except to the extent of pecuniary interest.
Rallybio Corp, a pharmaceutical company, is listed under NASDAQ:RLYB.
In other recent news, Rallybio will receive a $50 million termination fee following the collapse of its planned merger with Candid Therapeutics. Candid terminated after entering an alternative agreement with UCB S.A. Additionally, Rallybio announced the departure of its Chief Medical Officer, Steven Ryder.
